SELLAS Life Sciences Group (SLS) Competitors $1.80 -0.03 (-1.64%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$1.82 +0.01 (+0.83%) As of 07/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLS vs. URGN, PHAR, MGTX, GYRE, MNMD, ZVRA, DNTH, DAWN, ATAI, and AUTLShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Urogen Pharma (URGN), Pharming Group (PHAR), MeiraGTx (MGTX), Gyre Therapeutics (GYRE), Mind Medicine (MindMed) (MNMD), Zevra Therapeutics (ZVRA), Dianthus Therapeutics (DNTH), Day One Biopharmaceuticals (DAWN), atai Life Sciences (ATAI), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. SELLAS Life Sciences Group vs. Its Competitors Urogen Pharma Pharming Group MeiraGTx Gyre Therapeutics Mind Medicine (MindMed) Zevra Therapeutics Dianthus Therapeutics Day One Biopharmaceuticals atai Life Sciences Autolus Therapeutics SELLAS Life Sciences Group (NASDAQ:SLS) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends. Which has higher earnings and valuation, SLS or URGN? SELLAS Life Sciences Group has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSELLAS Life Sciences GroupN/AN/A-$30.88M-$0.38-4.74Urogen Pharma$90.40M9.68-$126.87M-$3.18-5.96 Do analysts rate SLS or URGN? SELLAS Life Sciences Group presently has a consensus price target of $7.00, indicating a potential upside of 288.89%. Urogen Pharma has a consensus price target of $32.86, indicating a potential upside of 73.39%. Given SELLAS Life Sciences Group's higher probable upside, equities research analysts plainly believe SELLAS Life Sciences Group is more favorable than Urogen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is SLS or URGN more profitable? SELLAS Life Sciences Group has a net margin of 0.00% compared to Urogen Pharma's net margin of -150.68%. SELLAS Life Sciences Group's return on equity of -193.67% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences GroupN/A -193.67% -113.02% Urogen Pharma -150.68%-97,487.15%-49.57% Does the media favor SLS or URGN? In the previous week, Urogen Pharma had 7 more articles in the media than SELLAS Life Sciences Group. MarketBeat recorded 8 mentions for Urogen Pharma and 1 mentions for SELLAS Life Sciences Group. SELLAS Life Sciences Group's average media sentiment score of 1.89 beat Urogen Pharma's score of 0.55 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Overall Sentiment SELLAS Life Sciences Group Very Positive Urogen Pharma Positive Which has more volatility and risk, SLS or URGN? SELLAS Life Sciences Group has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Do institutionals and insiders hold more shares of SLS or URGN? 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 1.4% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 5.1% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummarySELLAS Life Sciences Group beats Urogen Pharma on 8 of the 15 factors compared between the two stocks. Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$179.60M$3.05B$5.70B$9.50BDividend YieldN/A2.37%4.58%4.00%P/E Ratio-4.7421.3228.3920.08Price / SalesN/A285.38431.7788.79Price / CashN/A42.7636.2258.56Price / Book13.858.378.675.88Net Income-$30.88M-$55.19M$3.25B$258.89M7 Day Performance1.69%5.86%4.30%3.71%1 Month Performance-11.33%17.29%10.57%11.72%1 Year Performance53.85%4.39%35.68%18.00% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group2.323 of 5 stars$1.80-1.6%$7.00+288.9%+55.2%$179.60MN/A-4.7410URGNUrogen Pharma4.5124 of 5 stars$15.46+1.2%$32.86+112.5%+15.8%$705.49M$90.40M-4.86200High Trading VolumePHARPharming Group2.2878 of 5 stars$10.14-1.0%$30.00+195.7%+20.7%$702.52M$297.20M-50.72280News CoverageUpcoming EarningsGap UpMGTXMeiraGTx4.2731 of 5 stars$8.69+0.8%$24.00+176.2%+64.4%$692.75M$33.28M-3.75300Insider TradeGYREGyre Therapeutics0.1464 of 5 stars$7.10-1.5%N/A-49.0%$676.00M$100.64M355.1840Positive NewsMNMDMind Medicine (MindMed)1.9796 of 5 stars$9.95+12.0%$25.50+156.3%+3.6%$670.91MN/A-7.7140News CoverageUpcoming EarningsHigh Trading VolumeZVRAZevra Therapeutics3.0903 of 5 stars$11.73-2.8%$23.71+102.2%+80.3%$659.98M$23.61M-6.1720DNTHDianthus Therapeutics1.3253 of 5 stars$20.74+1.7%$53.00+155.5%-23.5%$656.06M$6.24M-7.2080Positive NewsDAWNDay One Biopharmaceuticals2.7115 of 5 stars$6.40flat$29.00+353.1%-54.5%$648.72M$131.16M-9.0160News CoverageATAIatai Life Sciences3.3112 of 5 stars$3.53+9.3%$9.00+155.0%+125.9%$647.09M$310K-3.8880News CoverageHigh Trading VolumeAUTLAutolus Therapeutics2.6132 of 5 stars$2.43+0.8%$9.32+283.5%-45.2%$641.40M$10.12M-2.76330 Related Companies and Tools Related Companies Urogen Pharma Alternatives Pharming Group Alternatives MeiraGTx Alternatives Gyre Therapeutics Alternatives Mind Medicine (MindMed) Alternatives Zevra Therapeutics Alternatives Dianthus Therapeutics Alternatives Day One Biopharmaceuticals Alternatives atai Life Sciences Alternatives Autolus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLS) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
